Press Release

Human Insulin Market Thrives in Response to The Increasing Diabetes Cases

The Global Human Insulin Market is projected to grow at a CAGR of 5.4% in the forecast period of 2023-28, cites MarkNtel Advisors in the recent research report. The market growth is predominantly driven by the increasing diabetes population globally and the surging exposure of people to diabetes-inducing risk factors such as a sedentary lifestyle and obesity. In addition, advancement, research, and development in numerous insulin products, resulting from the competition amongst the major market participants and investments of healthcare organizations and countries, has produced new product launches and variations of insulin, accelerating industrial growth, states the research report, “Global Human Insulin Market Analysis, 2023.”

Segmentation Analysis

The market is broadly fragmented based on Product Type and Applications. The product Type segment is segmented into Human Insulin Drugs and Human Insulin Delivery Devices. Further classification of Human Insulin Drugs sub-segment includes Insulin Analogs & Biosimilars and Human Insulin Biologics in which the Insulin Analogs & Biosimilars are distributed among Long Acting Biosimilars, Rapid Acting Biosimilars, and Premixed Biosimilars. In contrast, Human Insulin Biologics are distributed among Short Acting Biologics, Intermediate Acting Biologics, and Premixed Biologics.

Furthermore, the Human Insulin Delivery Devices sub-segment is segmented into Syringes, Pens, and Pen Needles, where Pens are divided between Disposable Pens and Reusable Pens. In contrast, Pen Needles are divided between Standard Pen Needles and Safety Pen Needles. Finally, based on Application, the market is segmented into Type I Diabetes and Type II Diabetes.

Low Risk & High-Efficiency Awards Insulin Analogs & Biosimilars The Higher Market Share

Insulin Analogs & Biosimilars Drugs are expected to dominate the market in the coming years, aided by higher adherence to therapy and better glycemic control compared to conventional human insulin biologics. Additionally, the reduced risk of hypoglycemia and other adverse effects of insulin, along with increased efficacy and response rate, has shifted consumer preference to insulin analogs, driving the market. Moreover, the user-friendly operability, portability, and easy installation of delivery devices of premixed biosimilars have further boosted industrial expansion.

Presence of Major Market Players Pushes North America to The Front

Globally, North America is expected to garner the largest market share during the forecasting period. The growth is credited to the constant prevalence of diabetes in combination with the presence of significant market players and participants in the region. In addition, the rising fierce competition amongst businesses and the existence of an advanced healthcare system leading to easier patient access to diagnosis and treatment have helped the area garner a significant portion of the overall market.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market players, including B.Braun (B. Braum Melsungen), Becton, Dickinson and Company (BD), Biocon Limited, Biodel Inc., Eli Lilly and Company, Julphar (Gulf Pharmaceutical Industry), Novo Nordisk A/S, Sanofi, Wockhardt Ltd., and The Ypsomed Group are looking forward to strengthening their market position.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends that have shaped the industry to its current form?
3. What key factors would propel and impede the Global Human Insulin Market?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition shaped across various countries, followed by their comparative factorial indexing?
6. How have buying behavior, customer inclination, and expectations from Human Insulin manufacturers evolved during 2018-28?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?